Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine for Oxygenation in Morbidly Obese Patients
NCT02843698Phase 4Completed
- Sponsor
- Cairo University
- Start
- Sep 2016
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of dexmedetomidine in restrictive lung disease (RLD) (2 arms), sponsored by Cairo University. Primary endpoint: Oxygenation (PF ratio) at 2 hours. Started Sep 2016; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
restrictive lung disease (RLD)
Beyond the preview
Go deeper on NCT02843698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02843698.